Go to AAD Home
Donate For Public and Patients Store Search
Go to AAD Home
Main menu
Membership
Meetings & Education
Practice management
Clinical & quality
Publications & apps
Career development
Advocacy
Back
Account
Pay dues
Member ID
Join the AAD
Member benefits
Find a member
AAD governance
Support AAD
Community Programs
AAD Help Center
2026 Annual Meeting
2026 Innovation Academy
Academy meetings archive
Professional education
Claim CME & view transcript
Upcoming events
Residents & medical students
Patient education materials
DataDerm
Coding Resource Center
MIPS & fee schedule
Teledermatology
EHR & health tech
Insurance & drugs
Compliance & practice scope
Managing your practice
Contact PM staff
Clinical guidelines
Quality measures
DataDerm
Quality & patient safety
Clinical Community
Clinical care resources
Position statements
JAAD
JAAD International
JAAD Case Reports
Dermatology World
DermWorld Insights & Inquiries
Derm Coding Consult
DermWorld Meeting News
Impact Report
Other publications
Academy Apps
Career launch
Job board
Burnout & wellness
Diversity
Awards, grants, and scholarships
Leadership Institute
Volunteer opportunities
Ethics & professionalism
Take action
Advocacy priorities
State advocacy resources
Legislative Conference
Position statements
Promote the specialty
Key Contacts
Patient advocate resources
SkinPAC
Advocacy Update
Welcome!

American Academy of Dermatology Association statement on FDA iPLEDGE changes reducing burdens on both prescribers and patients

Statement from Susan C. Taylor, MD, FAAD, President, American Academy of Dermatology

ROSEMONT, Ill. (Feb. 10, 2026) — The American Academy of Dermatology Association applauds the Food and Drug Administration for approving significant changes to the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program. These changes will reduce substantial administrative burdens for both prescribers and patients while maintaining patient safety.

The Academy has been advocating for many years to reduce burdens associated with iPLEDGE for both physicians and patients and improve access to isotretinoin to help improve our patients’ lives.

# # #

Contact

Shelby Homiston, shomiston@aad.org

Media Relations, mediarelations@aad.org

About the AAD

Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 21,800 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on  Facebook, TikTok, Pinterest, and YouTube, and @AADskin1 on Instagram.